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Available online 11 October 2016Objective: This was a prospective, single-center study evaluating the efﬁcacy and cost-effectiveness of early am-
bulation (within 30 min) following femoral artery closure with the ProGlide® suture-mediated vascular closure
device (PD) in patients undergoing diagnostic cardiac catheterization compared with manual compression.
Background: It is unclear whether early ambulation with ProGlide is safe or is associatedwith patient satisfaction
and cost savings as compared with manual compression (MC).
Methods and results: Inclusion criteria were met in 170 patients (85 PD and 85MC patients). Patients ambulated
20 ft. within 30 min (PD) or after the requisite 4 h recumbent time (MC) if feasible. Primary endpoint was time-
to-ambulation (TTA) following device closure. We also directly compared the safety of closure, times-to-
hemostasis (TTH), -ambulation (TTA) and -discharge (TTD) with MC and, using a fully allocated cost model,
performed cost analysis for both strategies. Multivariate analysis was used to determine predictors of patient
satisfaction. The primary endpoint of safe, early ambulation was achieved following closure (mean of 27.1 ±
14.9min; 95% conﬁdence interval [CI] 25.2–30.2). Predictors of patient satisfaction in the PD groupwere absence
of pain during closure, decreased TTA, and drastic reductions in TTD; the latter contributed indirectly to
signiﬁcant cost savings in the PD group (1250.3 ± 146.4 vs. 2248.1 ± 910.2 dollars, respectively; P b 0.001)
and incremental cost savings by strategy also favored closure over MC ($84,807).
Conclusions: ProGlide is safe and effective for femoral artery closure in patientswho ambulatewithin 30min after
cardiac catheterization; translating into improved patient satisfaction and substantial cost savings.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cardiac catheterization1. Introduction
Femoral artery cannulation continues to be the predominant route
for vascular access in coronary and structural heart interventions in
the United States (US) despite the increasing use of radial artery access
[1–3]. However, femoral artery access site bleeding complications carry
an increased morbidity and mortality as compared to other access
routes [4]. Therefore, proﬁciency with arterial puncture and closure
(either manual or device-related) is crucial and plays a vital role in thenual compression; PD, Perclose
to-ambulation; TTD, time-to-
s, Division of Cardiovascular
dd Heart and Lung Center, 201
ited States.
y).
land Ltd. This is an open access articlsafety of diagnostic cardiac catheterization (cath).Minimizing femoral ar-
tery access site complications remains the rationale for the introduction
and widespread use of vascular closure devices (VCD). However, with
the wide variety of devices available each with unique mechanisms for
vessel closure, the safety and efﬁciency of access site management
using VCDs remains controversial. Large meta-analyses, registry and
single-center studies provide conﬂicting data regarding VCD-related vas-
cular complication event rates as compared with manual compression
(MC) [5–10]. Of the major advantages of VCDs, reduced time-to-
ambulation (TTA), when associated with no increase in vascular compli-
cations [11], is among the most desirable in terms of patient satisfaction
and cost-effectiveness [12,13]. A wide variety of closure devices are cur-
rently available for use, each classiﬁed based on their method of closure;
either collagen or procoagulant-based (e.g., Angioseal®, St. Jude Medical,
St. Paul, MN), clip/staple-based (e.g., Starclose®, Abbott Scientiﬁc, Abbott
Park, IL) or suture-mediated (e.g., Perclose ProGlide® and ProStar®,
Abbott Scientiﬁc, Abbott Park, IL) [14].e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Major inclusion and exclusion criteria.
Major inclusion criteria
Candidates for elective cardiac diagnostic catheterization performed
percutaneously via the right or left femoral arterial approach
Vessel size N5 mm by visual estimate
Access using 5F or 6F introducer sheath
Conﬁrmed angiographic absence of current or previously treated signiﬁcant (≥50%
stenosis) femoral artery atherosclerosis
Lack of obvious ﬂuoroscopic evidence of signiﬁcant femoral vessel calciﬁcation
Conﬁrmed post-procedural puncture site between the common femoral artery
bifurcation and inferior border of the inferior epigastric artery
Major exclusion criteria
Vessel size b5 mm by visual estimate (or plaque burden resulting in lumen b5 mm)
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suture-mediated VCDs in the setting of percutaneous coronary inter-
vention, there are no data directly comparing femoral vessel closure
using ProGlide (PD; the most recent generation in the Perclose device
series) with manual compression, speciﬁcally following diagnostic car-
diac cath. Moreover, whether patients can be safely ambulated and
discharged early following femoral artery closure has only been demon-
strated oncewith the StarClose VCD [12]. To date, this has not been pro-
spectively evaluated with the Perclose devices. Here, we assessed
prospectively, the safety and efﬁcacy of early ambulation following
use of ProGlide in patients undergoing diagnostic cardiac catheteriza-
tion as compared to MC. We further assessed patient satisfaction and
the cost-effectiveness of ProGlide-mediated vessel closure versus MC.Inability to control post-procedural hypertension in the cath lab (systolic ≥180 mm Hg,
diastolic ≥100 mm Hg)
Inability to ambulate 20 ft due to co-morbidity or functional limitation
Access site complications prior to ProGlide deployment2. Methods
2.1. Patient population and study design
This study was a prospective study approved by the institutional re-
view board at the University of Louisville School of Medicine (Louisville,
Kentucky) and conducted at a single, high-volumequaternary-care cen-
ter in Louisville Kentucky. Baseline patient characteristics are shown in
Table 1. Two hundred and twelve consecutive patients presenting from
April to June (2012) for elective diagnostic cardiac cath using either the
right or left femoral arterial approach signed an informed consent. One
hundred and seventy of these patients met entry criteria (Table 2) and
were enrolled. Screen failures were excluded based on clinical and/or
angiographic criteria. Catheterizationswere performed under conscious
sedation, using 5 or 6 French AvantiPlus® (Cordis, Bridgewater, NJ) or
Pinnacle® (Terumo, Somerset, NJ) sheaths. We comparedmanual com-
pression (85 patients) to vessel closure using the ProGlide suture-
mediated VCD (PD) (85 patients). Of the six board-certiﬁed interven-
tional cardiologists deploying the PD in the study, all had greater than
three years (range 3.2–9 years) of experience using Perclose devices.Table 1
Baseline characteristics of 170 patients enrolled.
Demographic characteristics
ProGlide Manual compression P
n = 85 n = 85
Age — year
Mean 60 ± 12 59 ± 10 NS
Male sex — no. (%) 73 (86) 76 (89) NS
Race — no. (%)
White 64 (75) 66 (78) NS
Black 20 (24) 17 (20) NS
Asian 0 (0) 2 (2) NS
Other 1 (1) 0 (0) NS
Body mass index (BMI)a
Mean 27 ± 3.0 25 ± 4.0 NS
Hypertension — no. (%) 70 (82) 64 (75) NS
Diabetes — no. (%) 36 (42) 37 (44) NS
Dyslipidemia — no. (%) 54 (63) 61 (72) NS
Smoking — no. (%) 66 (78) 65 (77) NS
Current 34 (52) 39 (60) NS
Previous 32 (48) 26 (40) NS
Family history CAD — no. (%) 30 (35) 21 (25) b0.05
Procedure characteristics
Pre-procedural angiography — no. (%) 85 (100) 85 (100) NS
Retrograde puncture — no. (%) 85 (100) 85 (100) NS
Right groin approach — no. (%) 78 (92) 83 (98) NS
Vessel diameter ≥5.0 mm — no. (%) 85 (100) 85 (100) NS
Continuous data are presented as means ± SD; categorical data are presented as counts
(percentages).
a Body mass index is the weight in kilograms divided by the square of the height in
meters.2.2. Study device description
The ProGlide is the ﬁfth generation of the single-use 6F disposable
suture-mediated Perclose devices that delivers two needles and a single
suture through the arterial wall (adventitia to lumen) for closure of the
femoral arteriotomy following percutaneous diagnostic or intervention-
al cath or peripheral procedures that utilize 5–21F sheaths. The ProGlide
single device delivery system is for usewith any 0.035 in. guidewire and
contains a “knot-pusher”. Further details of its use have been previously
reported [14].2.3. Procedural deﬁnitions and study variables
All patients underwent pre-procedural ﬂuoroscopy-guided identiﬁ-
cation of the mid-femoral head to determine the puncture site. Post-
cardiac cath femoral angiography was performed on all patients. In pa-
tients whomet inclusion criteria (Table 2), hemostasis was achieved ei-
ther by (i) placement of the PD with a check for hemostasis made and
time recorded, or (ii) following transfer to holding formanual compres-
sion. If immediate hemostasis was not achieved manual compression
was performed for 3min and additional adjunctive compression follow-
ed as necessary; not to exceed 5 min (min) or device success was not
achieved. If additional time for manual compression was required, this
time was recorded. In the MC group, manual compression was per-
formed by experienced cath lab nurses with the application of a
Neptune® hemostasis Pad(s) (TZ Medical Inc., Portland, OR) and the
holding time was determined by the French size of the sheath used;
with 3 min of compression per French size being the standard. If after
15 (5F) or 18 (6F) min, hemostasis was not achieved, manual pressure
was held for additional 5 min increments until hemostasis was
achieved. The time inmin from removal of sheath to when no compres-
sion was required to control bleeding at the access site was deﬁned as
time-to-hemostasis (TTH). Mechanical compression devices were not
used as an adjunct to achieve hemostasis in any patient.
Once hemostasis was achieved, patients were ambulated. Prior to
ambulation, the access site was assessed for bleeding and/or complica-
tions. The primary endpoint for the study was mean TTA following PD
artery closure. Early ambulation was deﬁned as TTA ≤30 min in the PD
patients and the requisite recumbent time for MC patients was 4 h
from TTH. The 4 h limit for the MC group is an institutional policy and
consistent with previous reports [15,16] and was followed to ensure
congruence between groups when assessing complication rates.
Patients in the device group underwent a ‘challenge test’ consisting of
simultaneous head and leg lifts to assess the adequacy of hemostasis.
Those in the PD group who did not achieve hemostasis within 5 min
of device deployment or who converted to manual compression were
ambulated at the discretion of the interventionalist to ensure patient
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lating. Time-to-ambulation (TTA) was deﬁned as the time in min from
hemostasis to the time that the patient ambulated 20 ft without assis-
tance or re-bleeding. Patients with persistent access site issues were
managed and those methods were recorded.
Patients were discharged once satisfactory ambulation was achieved,
access sites were appropriately managed, and access site pain was toler-
able. Post-deployment time-to-discharge (TTD) was deﬁned as the
elapsed time from achievement of sheath removal to the time when
the patient was medically able to be discharged.
Procedural success and closure method complications were record-
ed (Table 3). Surgical complications speciﬁc to the closure device were
as follows: rupture or perforation of femoral artery, need for surgical
removal of device needle(s) and capture of vessel posterior wall with
resultant vessel occlusion.
Patient's overall satisfaction was evaluated by questionnaire using a
previously validated scoring method that included the Visual Analog
Scale (VAS-11) point system [12,17,18] and addressed the following:
(i) intensity of access site pain during closure and prior to discharge;
(ii) TTH; (iii) TTA; (iv) TTD; and (v) overall general satisfaction. Pain in-
tensity was speciﬁcally assessed using a Visual Analog Scale (VAS-11)
point system that ranked the level of patient discomfort at access site
was based on a pain scale of 0–11 (0 for no pain, 11 for pain being as
bad as imaginable for this procedure) taken during two distinct time
points: during closure and prior to discharge. Classiﬁcation of pain
was as follows: no pain (0), mild pain (1–3), mild to moderate pain
(4–7) moderate to severe pain (8–10) and severe pain (11). To deter-
mine overall patient satisfaction, patients were asked to rank their ex-
perience based on a satisfaction scale of 0–11 (0 for the worst
experience imaginable and 11 for the best experience imaginable for
this procedure). Classiﬁcation of overall satisfaction with their proce-
dural experience was as follows: worst (0), very bad (1–2), bad (3–4),
indifferent (5–6), good (7–8), very good (9–10), and best imaginable
(11). Those who had previous cardiac caths (from any access site) com-
pared the present to previous procedures.
Cost analysis was performed using a fully allocated cost model [19].
Total direct costs (costs of the device, infrastructure, and personnel)
were compared between both groups for the year 2012 (reported in US
dollars). The analysis was based on the actual institutional cost of equip-
ment used (e.g., closure device and/or hemostatic pad) and theTable 3
Procedural success and vascular complications.
Variable
Device success (%)a
Procedural success (%)b
Major vascular site complications
Need for surgical vascular repair
Ultrasound-guided compression, stent graft deployment or catheter-based embolization
Ipsilateral limb ischemia (decreased or absent distal Doppler signal, or poor distal run-o
Transfusion of any blood products required for access site-related bleeding (Hb drop ≥3
Overall (major)
Minor vascular site complications
Non-surgical access site complications
Access site hematoma b6 cm
Access site hematoma N6 cm
Access site persistent oozing
Femoral bruit
Pulsatile mass
Hemoglobin drop (above 3 g/dL) without need for transfusion
US guided compression for pseudoaneurysm
Overall (minor)
Overall complications
Data are presented as counts (percentages). MC=manual compression.
a Deﬁned as freedom from major vascular complications following achievement of complete
b Deﬁned as freedom from major vascular complications following achievement of completinstitutional costs for post-procedural management (which included in-
dividual nursing costs per patient treated and cost for hospitalization).
Hospitalization costs were determined prospectively. In-hospital unit
costs and length of stay costs were adjusted to reﬂect ancillary imaging
and blood bank needs (e.g., ultrasound and red blood cell transfusion)
and also included ﬁxed costs obtained from our hospital cost model for
a 24–72 h period. For a national comparison of per patient costs, refer
to http://www.ahaonlinestore.com/ProductDisplay.asp?ProductID=
637. The effect of recumbent time prior to ambulationwas further exam-
ined using sensitivity analysis to determine whether a cost advantage
existed between protocols (PD vs. manual compression).
2.4. Study endpoints
The primary endpoint of this study was mean TTA following PD clo-
sure; with ‘early ambulation’ in the PD arm deﬁned as TTA ≤30 min
without re-bleeding. Our secondary endpoints were TTH and TTD
alongwith analysis of patient safety (determined by procedural success
and access site complications), satisfaction (determined by patient
questionnaire after hemostasis and prior to discharge), and the cost-
effectiveness of the strategy used. Safety of closure method used was
measured by procedural (device) success, and procedure-related
major and minor complications. Variables used to measure efﬁcacy of
closure method were the TTH, TTA, and TTD.
2.5. Statistical analysis
Categorical data are expressed as frequency counts and percentages
and continuous data are expressed as mean ± SD or as median and in-
terquartile ranges (IQR) when variables lacked a normal distribution.
Categorical data were compared using χ2 or Fisher's exact tests. Contin-
uous data were compared between groups using two-tailed Student's
t-tests or Wilcoxon rank-sum test as appropriate. Univariate and multi-
variate analyses were performed using stepwise logistic regression to
identify factors associated with an overall satisfaction rating of ≥9.
Covariates with P b 0.1 in the univariate analysis were entered into
themultivariate model. Odds ratios (ORs) and 95% conﬁdence intervals
(CIs) were reported for continuous and categorical data. P b 0.05 was
considered statistically signiﬁcant. All statistical analyses weren = 85 n = 85 P
ProGlide MC
85 (100) (NA) NA
85 (100) 82 (96) 0.12
0 (0) 0 (0) NA
0 (0) 0 (0) NA
ff by lower extremity angiogram) 0 (0) 0 (0) NA
g/dL) 0 (0) 3 (3.5) 0.25
0 (0) 0 (0) NA
2 (2.4) 1 (1.2) 0.56
0 (0) 4 (4.7) b0.05
1 (1.2) 2 (2.4) 0.56
0 (0) 0 (0) NA
0 (0) 0 (0) NA
0 (0) 0 (0) NA
0 (0) 0 (0) NA
3 (3.5) 7 (8.2) 0.33
3 (3.5) 10 (11.8) 0.08
hemostasis using the Perclose alone or with adjunctive compression of ≤5 min.
e hemostasis using any method.
9A. Sekhar et al. / IJC Heart & Vasculature 13 (2016) 6–13performed using the SPSS (version 19) statistical software (SPSS, Inc.,
Chicago, Illinois).
3. Results
3.1. Subject enrollment
A total of 212 consecutive patients undergoing diagnostic cardiac
cath were screened and 170were not excluded by angiographic or clin-
ical criteria and were enrolled at a single center (42) excluded based on
criteria outline in Table 2: hypertension (8), ambulation (2), calciﬁca-
tion (12), stenosis (15), and vessel size (5). Eighty-ﬁve patients received
standard MC and 85 received percutaneous closure with the ProGlide
suture-mediated VCD. Baseline characteristics are listed in Table 1.
Overall, each group was similar demographically and procedurally.
3.2. Device safety
The overall safety and performance of the procedure was measured
by procedural success and device success (Table 3). The PDwas success-
fully deployed in 100% of patients attempted; one patient required
rewiring and an additional device due to suture breakage of the ﬁrst de-
vice. Manual compression was successful in all but three patients
(Table 3). In the PD group one patient experienced persistent oozing
from the access site and two had small hematomas (b6 cm). In the
MC group, two patients experienced persistent oozing and four had
large hematomas (N6 cm). Taken together, these minor complications
were not signiﬁcantly different between the 2 groups (Table 3, PD =
3.5% and MC = 8.2%; P= 0.33). There were no major complications in
the PD group and no deaths or retroperitoneal bleeds in either group.
Three patients in the MC group required blood transfusions due to sig-
niﬁcant access site bleeding (Hb drop ≥3 g/dL) which was not seen in
the PD group; yet, this difference was merely a trend (Table 3, PD =
0.0% and MC = 3.5%; P= 0.25).
3.3. Closure method efﬁcacy
Patients with major complications requiring hospitalization were
excluded from this analysis (3 patients in the MC group). As depicted
in Table 4, our primary endpoint of TTA was met in the PD group with
the majority of patients ambulating early following PD closure (mean
TTA 27.1 ± 14.9 min; 95% conﬁdence interval [CI] 25.2–30.2). As ex-
pected, TTA was reduced substantially in the PD group as compared to
MC (mean TTA of 27.1 ± 14.9 min and 4.13 h ± 28.9 min, respectively;
Fig. 1, P b 0.001). Time-to-hemostasis was compared between the two
groups; PD patients had a signiﬁcantly lower TTH (Fig. 1, P b 0.001).
Post-deployment TTD was drastically reduced in the PD group with a
mean TTD of 59.6 (± 41.7) min compared to MC (mean of 5.8 h ±
30.6 min; Fig. 1, P b 0.001).
3.4. Patient satisfaction
Overall patient satisfaction including procedure-related pain
intensity was assessed peri-procedurally. Mean pain scores on a scale
of 0–11 during closure/compression for PD and MC groups wereTable 4
Primary study endpoint.
Variable
ProGlide Group
n = 85 95% CI
Time-to-ambulation (min)
Mean ± SD 27.1 ± 14.9 25.2–30.2
Median (IQR) 20 (20–76) 19.5–24.6
Data are time in minutes: mean ± SD and median (interquartile ranges [IQR]). CI = con-
ﬁdence interval.1.4 ± 2.11 and 4.3 ± 2.51, respectively (P b 0.05). During closure/man-
ual compression, patients reporting a pain scale of “0” (no pain) was
62.4% (53/85) in the PD group, and 37.6% (32/85) in the MC group
(P b 0.001), with 94.1% (80/85) of PD and 70.6% (60/85) of the MC pa-
tients reporting pain scales ≤7 (≤moderate pain, P b 0.001); only 5.9%
(5/85) of PD patients reported moderate-to-severe (8–11) compared
to 29.4% (25/85) of MC patients (Fig. 2A, P b 0.001). Prior to discharge,
97.6% (83/85) of PD and 68.2% (58/85) of MC patients reported pain
levels ≤moderate (P b 0.001); only 2.4% (2/85) of PD patients reported
moderate-to-severe pain compare to 31.8% (27/85) of MC patients
(Fig. 2B, P b 0.001). No patients in either group were completely free
of pain or discomfort at discharge (mean pain scores at discharge
were 0.53 ± 0.93 and 4.1 ± 2.63 for PD and MC groups, respectively)
(Fig. 2B, P b 0.05).
Forty-ﬁve percent of PD patients and 55% of MC patients underwent
previous cardiac cath (P = 0.22). Patients in the PD group reported a
signiﬁcantly higher satisfaction with their procedure compared previ-
ous caths (9.6 ± 0.5 versus 6.5 ± 0.9, respectively; P b 0.001, Fig. 2C).
Likewise, patients undergoing closure reported a signiﬁcantly higher
overall satisfactionwith their procedure compared to patients undergo-
ing MC (10.6 ± 0.3 versus 6.4 ± 0.4, respectively; P b 0.001, Fig. 2C).
Multivariate analysis demonstrated that patients in the PD group
who reported a ‘very good’ or better procedural experience (≥9) were
~5-fold more likely to report no pain during closure (Table 5; odds
ratio [OR] 5.11; 95% CI 3.12–8.35; P b 0.01). Both decreased TTA (OR
3.18; 95% CI 1.34–5.36; P b 0.01) and TTD (OR 4.61; 95% CI 2.54–6.21;
P b 0.01) also predicted patient's overall satisfaction in favor of PD
over MC (Table 5). In both MC (OR 1.01; 95% CI 0.98–1.03; P = 0.04)
and PD groups (OR 2.01; 95% CI 1.10–3.67; P= 0.02), ≤moderate pain
was more often associated with increased overall patient satisfaction
(Table 5).
3.5. Cost analysis
Table 6 compares the institutional cost per closure strategy.With the
exception of themean additional cost of ProGlide (278.2± 77.4 dollars)
use per-patient versus the mean cost of Neptune Pads used per-patient
(41.6 ± 22.4 dollars), per-patient institutional costs were signiﬁcantly
reduced when the ProGlide closure system was used (P b 0.001).
When considered in the absence of hospitalizations (100% of which
occurred in the MC group; P b 0.001), savings in catheterization lab
holding and nursing expense accounted for the majority of the average
total cost savings (117.7% and118.9% reductions in average cost, respec-
tively; P b 0.001).When compared toMC, a cost savings of almost $1000
per-patient was observed in PD group (Table 6; 1250.3 ± 146.4 versus
2248.1 ± 910.2 dollars, respectively; P b 0.001). The incremental cost
savings by closure strategy also favored the use of ProGlide over MC in
this study (Table 6; $106,278.70 versus $191,086.50). Sensitivity analy-
sis was performed (comparing the cost of bed-time [TTA] between
groups) to better understand how varying the mandatory recumbent
times in the MC group, driven by our institutional protocol, might
impact the demonstrated cost savings. We found the PD strategy to be
cost-effective so long as TTD in the MC group was ≥64 min, as it was
in all MC cases. As such, even when shorter ambulation times are
considered (e.g., 2 h, the case in many US labs), our cost analysis
effectively estimates the cost beneﬁt of early ambulation when the PD
strategy is utilized.
4. Discussion
The primary objective of this single-center prospective study was to
determine whether early ambulation following femoral artery closure
using the newest version of the single-use 6F Perclose suture-
mediated ProGlide VCD was safe. To date, no study has compared the
efﬁcacy of early ambulation (within 30 min of closure) using Perclose
with manual compression in patients undergoing diagnostic cardiac
Fig. 1. Study endpoints. Upper panel: data are mean ± SD.
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strategy. The major ﬁndings of our study were the following:
1. To our knowledge, ours is the only prospective study using the
Perclose system to report safe early ambulation within 30 min of
closure. We also describe the earliest reported discharge time of
any femoral VCD following diagnostic cardiac cath (~60 min).
2. Predictors for greater patient satisfaction associated with the
use of the ProGlide were (i) a greater number of patients
undergoing painless vessel closure, (ii) very early TTA, and (iii)
timely TTD.
3. Despite the additional up-front cost of the ProGlide device compared
to MC, signiﬁcant reductions in cath lab and nursing time spent per-
patient drastically reduced the total direct costs of the procedure, pri-
marily due to very early discharge; driven further by lack of need for
hospitalization in the PD group.
Since the early days of cardiac catheterization, the femoral artery has
been the most widely used site for percutaneous access. Increased
access site bleeding and vascular complications were the driving forces
for the eventual elimination or miniaturization of the requisite bulky
equipment used during these procedures. Unfortunately, since the
subsequent reduction in sheath sizes (4, 5 and 6 French) did not
translate into reductions in bleeding complications or patient dis-
comfort [16], alternative methods for access site management
emerged. Accordingly, the current era of cardiac catheterization
has witnessed a resurgence of transradial artery access which has
since been shown to reduce vascular complications and major
access site bleeding [1,20]. As mechanical compression devices
demonstrated no clinically appreciable advantages in terms of femoral
access site management, the inevitable corollary was the development
of VCDs in an effort to eliminate or limit the risk, patient discomfort
and prolonged costly immobilization associated with manual compres-
sion [12,14].4.1. Safety and efﬁcacy
The most recent comprehensive meta-analysis collectively compar-
ing all three commercially available VCDs (Angioseal, Perclose, and
Starclose) showed no difference in complications rates when compared
toMC alone [8]. However, analysis of the suture-mediated VCD Perclose
relative to other VCDs conﬁrmed its safety particularly when used in di-
agnostic cases, suggesting that safety of VCDs is not a class effect [8,10].
Our study was not designed to simply verify the safety of the ProGlide
suture-mediated VCD relative to MC in patients who underwent diag-
nostic cardiac catheterization. Insteadwe sought to thoroughly evaluate
the efﬁciency of ProGlide-mediated femoral artery closure in terms of
safe, early TTA and TTD and further assess patient experience and the
economic value of each hemostasis strategy. Previous prospective trials
evaluating the safety of VCDs versus manual compression during inva-
sive cardiac procedures reported similar procedural success and compli-
cation rates [15,17,21–24]. However, to our knowledge this is the ﬁrst
prospective study using a Perclose VCD to clearly demonstrate the safe-
ty of early ambulation (within 30 min) following any type of cardiac
catheterization. With the exception of a small subset of patients (2.2%)
in a single study whowere ambulated in the cath lab following Perclose
use [21], only one other study has reported early ambulation times
(within 30 min) following the use of a VCD after cardiac cath; in this
case, following use of the Starclose device [12]. In the former study, no
speciﬁc effortwasmade to ambulate patients early. Instead, closure suc-
cess determined ambulation times and TTA was left to the discretion of
the nursing team with the overwhelming majority of patients (~80%)
ambulating between 2 and 6 h [21].4.2. Satisfaction
Given the discomfort related the mechanical compression of the
femoral artery following cardiac catheterization and the requisite
Fig. 2. Procedural patient satisfaction. Procedural discomfort was assessed following hemostasis (A) and prior to discharge (B) achieved using either suture-mediated vessel closure
(ProGlide) or manual compression (Manual). Data are frequency counts by questionnaire expressed as percentages. (C) Overall patient satisfaction was assessed prior to discharge on
a scale of 0–11. Data are mean ± SD.
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Table 5
Factors associated with patient satisfaction (score of ≥ 9).
Variable Odds ratio 95% CI P
Pain intensity (during closure/compression)
MC
No pain 1.06 0.96–1.89 0.58
≤ moderate pain 1.01 0.98–1.03 0.04
PD
No pain 5.11 3.12–8.35 b0.01
≤ moderate pain 2.01 1.10–3.67 0.02
Time savings
MC
Time-to-ambulation (per minute decrease) 1.13 0.51–2.42 0.74
Time-to-discharge (per minute decrease) 1.07 0.83–1.62 0.62
PD
Time-to-ambulation (per minute decrease) 3.18 1.34–5.36 b0.01
Time-to-discharge (per minute decrease) 4.61 2.54–6.21 b0.01
Manual compression (MC), ProGlide device (PD) and conﬁdence interval (CI). Other co-
variates studied with P N 0.1 in the univariate analysis were: presence of hematoma (≤6
or ≥6 cm); no pain, ≤moderate pain, and ≤moderate-to-severe pain prior to discharge;
and time-to-hemostasis.
12 A. Sekhar et al. / IJC Heart & Vasculature 13 (2016) 6–13recumbent time required for effective manual compression, previous
investigators have attempted to qualify and quantify patient satisfaction
associated with various methods of groin hemostasis [12,13,15,17].
Whereas Baim et al. reported less discomfort in patients treated with
the older Techstar® and ProstarPlus suture-mediated systems in the
STAND trials [15], others found no difference in patient satisfaction
when either the older or newer ProGlide suture-mediated systems
were compared to MC [13,17]. In one of these studies evaluation of pa-
tient satisfaction was assessed only after 30 days, by telephone, and in
an undisclosed number of patients [17]; neither study was restricted
to patients undergoing diagnostic catheterization. An important distinc-
tion, considering that a major criterion reportedly driving patient satis-
faction was TTA: (i) which ranged from 2 to 4 h following diagnostic
cath; (ii) was greater than 7 h following intervention; and (iii) with
no stratiﬁcation of patient satisfaction based on procedure type
attempted. Greater patient satisfaction and reduced discomfort in our
study following the use of ProGlide were primarily driven by the ab-
sence of pain during closure in the vast majority of patients studied
and by the substantial reduction in TTA and TTD as compared patients
who underwent MC.Table 6
Institutional costs by closure strategy.
Hospital costs
Total procedural cost/patient, without hemostasis product — $
Mean ± SD
Hemostasis cost/patient — $a
Mean ± SD
Post-procedural cath lab holding/patient — $b
Mean ± SD
Total adjusted nursing costs/patient — $c
Mean ± SD
Hospital adjusted in-patient expenses/patient — intermediate level– $d
Mean ± SD
Total cost/patient — $
Mean ± SD
(Incremental savings — $)
Total cost/strategy — $
(Incremental savings — $)
All data are U.S. dollars ($): mean ± SD.
a All patients in the device group (ProGlide) received a ProGlide device ($197.9/device) ± N
only Neptune® Pad(s).
b Based on an institutional post-procedural cath lab holding cost per hour of $205 per patien
c Based on an adjusted nursing cost per hour of $67 per patient (extrapolated from adjusted
d Based on hospital adjusted expenses per in-patient day of $1551.4.3. Cost savings
In addition to impacting patient satisfaction, the economic conse-
quences of delaying ambulation were clearly illustrated in this study
translated into a delay in discharge. We report the earliest TTD to date
which proved to be the most economically relevant endpoint studied.
Here, we assessed cost using a fully allocated cost model without con-
sideration of accounting costs or “charges”. Our cost analysis uncovered
signiﬁcant cost savings on a per-patient basis driven primarily by the
reduction in time spent at our institution. This translated into tens of
thousands of dollars saved when ProGlide was utilized as a hemostasis
strategy versus manual compression. Sensitivity analysis further dem-
onstrated that the PD strategy remains cost-effective relative to MC
within most clinically relevant TTA or TTD timeframes.
4.4. Limitations
Given that this is a single-center non-randomized trial, there are
inherent limitations. First, the lack of randomization introduces the
possibility of selection bias particularly since only patients who were
clinically and anatomically suitable for closure underwent PD; though
randomization is difﬁcult in cohorts where post-procedural TTA is con-
troversial. Second, our single-center experience allows only for analysis
based on our routine clinical practice. Third, our study reported only in-
hospital outcomes without out-patient follow-up; thus, conclusions
about long-term consequences of closure strategy cannot be drawn.
Finally, given that access fees and charges always tend to be higher in
insured patients (albeit a large portion of our population) it is
possible that we grossly underestimated to cost savings reported in
our study [19].
4.5. Conclusions
The results of this prospective trial comparing ProGlide VCD to MC
indicate that a strategy of femoral artery closure using ProGlide is not
only safe but effective when patients ambulate within 30min following
diagnostic cardiac catheterization. These data clearly demonstrate that
procedural satisfaction associatedwith ProGlide suture-mediated vessel
closure is driven by absence of pain during closure, early TTA and very
early TTD; the latter being the primary inﬂuence behind the economic
beneﬁt to using the ProGlide strategy.ProGlide Manual P
n = 85 n = 85
564.5 ± 132.3 553.7 ± 121.0 0.37
278.2 ± 77.4 41.6 ± 22.4 b0.001
308.5 ± 78.8 1190.8 ± 333.6 b0.001
99.1 ± 41.1 389.5 ± 98.2 b0.001
0.0 2052.6 ± 250.2 b0.001
1250.3 ± 146.4 2248.1 ± 910.2 b0.001
(983.6)
106,278.70 191,086.50
(84,807.80)
eptune® Pads ($35.2/pad) while all in the manual compression group (Manual) received
t.
annualized nursing salary per nurse per year).
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